As on Wednesday, Niagen Bioscience Inc (NASDAQ: NAGE) got off with the flyer as it spiked 1.54% to $6.61, before settling in for the price of $6.51 at the close. Taking a more long-term approach, NAGE posted a 52-week range of $5.16-$14.69.
Nevertheless, stock’s Earnings Per Share (EPS) this year is 65.29%. This publicly-traded company’s shares outstanding now amounts to $79.64 million, simultaneously with a float of $52.67 million. The organization now has a market capitalization sitting at $527.52 million. At the time of writing, stock’s 50-day Moving Average stood at $6.90, while the 200-day Moving Average is $8.92.
Niagen Bioscience Inc (NAGE) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Niagen Bioscience Inc’s current insider ownership accounts for 34.01%, in contrast to 39.91% institutional ownership. According to the most recent insider trade that took place on Nov 14 ’25, this organization’s Chief Financial Officer bought 4,465 shares at the rate of 6.81, making the entire transaction reach 30,406 in total value, affecting insider ownership by 7,372. Preceding that transaction, on Nov 14 ’25, Company’s Chief Financial Officer bought 2,220 for 6.85, making the whole transaction’s value amount to 15,210. This particular insider is now the holder of 2,220 in total.
Niagen Bioscience Inc (NAGE) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.05 per share during the current fiscal year.
Niagen Bioscience Inc’s EPS increase for this current 12-month fiscal period is 65.29% and is forecasted to reach 0.29 in the upcoming year.
Niagen Bioscience Inc (NASDAQ: NAGE) Trading Performance Indicators
Let’s observe the current performance indicators for Niagen Bioscience Inc (NAGE). It’s Quick Ratio in the last reported quarter now stands at 3.29. Alongside those numbers, its PE Ratio stands at $27.16, and its Beta score is 2.34. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.23. Similarly, its price to free cash flow for trailing twelve months is now 25.01.
In the same vein, NAGE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.24, a figure that is expected to reach 0.02 in the next quarter, and analysts are predicting that it will be 0.29 at the market close of one year from today.
Technical Analysis of Niagen Bioscience Inc (NAGE)
Through scrutinizing the latest numbers posted by the [Niagen Bioscience Inc, NAGE], it can be observed that its last 5-days Average volume of 0.77 million was lower the volume of 0.96 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 45.73% While, its Average True Range was 51.83.
Raw Stochastic average of Niagen Bioscience Inc (NAGE) in the period of the previous 100 days is set at 7.42%, which indicates a major fall in contrast to 45.73% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.23 that was lower than 0.40 volatility it exhibited in the past 100-days period.
